VIVUS Inc. (VVUS)
-NasdaqGS 12.30 
0.24(1.91%) May 17, 4:00PM EDT|After Hours
:
12.30 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 12.54 |
|---|
| Open: | 12.63 |
|---|
| Bid: | 12.28 x 300 |
|---|
| Ask: | 12.42 x 300 |
|---|
| 1y Target Est: | 17.50 |
|---|
| Beta: | 1.08 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 12.20 - 12.71 |
|---|
| 52wk Range: | 9.86 - 31.21 |
|---|
| Volume: | 1,538,032 |
|---|
| Avg Vol (3m): | 2,465,460 |
|---|
| Market Cap: | 1.24B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.74 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Vivus Taps Into More Cashat Seeking Alpha(Sun 9:41AM EDT)
- 25 Belt-Busting Obesity Factsat Motley Fool(Sat, May 18)
- VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial StatemeEDGAR Online(Thu, May 16)
- VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior NotesGlobeNewswire(Thu, May 16)
- Weight Loss Isn't Just for Looking Good Anymoreat Motley Fool(Wed, May 15)
- Is Vivus a Buy at These Prices?at Wall St. Cheat Sheet(Wed, May 15)
- VIVUS INC FinancialsEDGAR Online Financials(Wed, May 15)
- Vivus to sell $200 million in convertible debtAP(Wed, May 15)
- Vivus - Mild Drama Continuesat Seeking Alpha(Wed, May 15)
- Will Obesity Drugs Gain Soon?at Motley Fool(Wed, May 15)
- VIVUS Announces Proposed Offering of Convertible Senior NotesGlobeNewswire(Wed, May 15)
- VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, May 15)
- Analysts: Market Is Beginning to Recognize Tesla and 3 Other Research Notes to Check Outat Wall St. Cheat Sheet(Tue, May 14)
- VIVUS Announces Scientific PresentationsGlobeNewswire(Tue, May 14)
- Looking at Arena Following Sell-Offat Motley Fool(Tue, May 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 206.13 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.90 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.44 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | -0.13 |
|---|
Business Summary
VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health.
View More